Trial · NCT02411643
Molecular Effects of Topical Calcipotriene on Morphea
NCT02411643, Early phase 1, Terminated, Northwestern University; results first posted 2018-09-13
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Molecular Effects of Topical Calcipotriene on Morphea. Trials, record NCT02411643. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02411643
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Molecular Effects of Topical Calcipotriene on Morphea
- NCT number
- NCT02411643
- Status
- Terminated
- Phases
- Early phase 1
- Enrollment
- 2 participants, actual
- Lead sponsor
- Northwestern University
- Conditions
- Morphea, Localized Scleroderma
- Interventions
- topical calcipotriene 0.005% ointment
- First posted
- 2015-04-08
- Last updated
- 2018-09-13
- Results first posted
- 2018-09-13
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change of Gene Expression From Skin Biopsy | day 0 and 3 months | Skin biopsy will be taken at day 0 and 3 months, RNA will be looked at for different gene expression levels |
| Secondary | Quality of Life | day 0 and 3 months | Quality of life questions will be asked at day 0 and 3 months |
| Secondary | Modified Localized Scleroderma Skin Score | day 0 and 3 months | The firmness or tightness of the skin will be measured throughout the body at day 0 and 3 months |
| Secondary | Change of Appearance of Skin Biopsy | day 0 and 3 months | Skin biopsy will be taken at baseline and 3 months, skin will be examined for expression levels of different proteins |
Source ClinicalTrials.gov
Outcomes4
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change of Gene Expression From Skin Biopsy | day 0 and 3 months | Study was terminated prior to obtaining results. | ||
| SECONDARY | Quality of Life | day 0 and 3 months | Study was terminated prior to obtaining results. | ||
| SECONDARY | Modified Localized Scleroderma Skin Score | day 0 and 3 months | Study was terminated before results were obtained. | ||
| SECONDARY | Change of Appearance of Skin Biopsy | day 0 and 3 months | Study was terminated before results were obtained. |
Source ClinicalTrials.gov
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Topical Calcipotriene 0.005% Ointment | 2 | |
| Overall Study | COMPLETED | Topical Calcipotriene 0.005% Ointment | 2 | |
| Overall Study | NOT COMPLETED | Topical Calcipotriene 0.005% Ointment | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Topical Calcipotriene 0.005% Ointment | ||
| Total, other adverse events | Topical Calcipotriene 0.005% Ointment | 0 | 2 |
| Total, serious adverse events | Topical Calcipotriene 0.005% Ointment | 0 | 2 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02411643
GET https://conductscience.org/api/trials/v1/NCT02411643/registered